


**Amendments to the Claims:** This listing of claims will replace all prior versions, and listings, of claims in the application

**Listing of Claims:**

1. - 20. (Cancelled)


21. (NEW) A compound of formula I:



in free or salt or solvate form, where

R<sup>1</sup> is hydroxy and R<sup>2</sup> is hydrogen;

G is a group having the formula Ib:



C~C denotes C=C or CH-CH;

R<sup>7</sup> and R<sup>8</sup> are both hydrogen;

R<sup>9</sup> and R<sup>10</sup> are independently selected from the group consisting of hydrogen and C<sub>1</sub>-C<sub>10</sub> alkyl, or R<sup>9</sup> and R<sup>10</sup> together form a C<sub>3</sub>-C<sub>10</sub> cycloalkyl or C<sub>3</sub>-C<sub>10</sub> cycloalkenyl, and in either case

wherein R<sup>9</sup> and R<sup>10</sup> are optionally substituted by C<sub>1</sub>-C<sub>10</sub> alkyl; and

R<sup>11</sup> is a C<sub>3</sub>-C<sub>15</sub> carbocyclic group or C<sub>1</sub>-C<sub>10</sub> alkyl substituted by a C<sub>3</sub>-C<sub>15</sub> carbocyclic group.

Restriction Requirement Dated May 8, 2009

Reply to Restriction Requirement Dated June 8, 2009

22. (NEW) The compound according to claim 21, wherein:

R<sup>1</sup> is hydroxy and R<sup>2</sup> is hydrogen;

C~C denotes C=C or CH-CH;

R<sup>7</sup> and R<sup>8</sup> are both hydrogen;

R<sup>9</sup> and R<sup>10</sup> are independently selected from the group consisting of hydrogen or C<sub>1</sub>-C<sub>4</sub> alkyl, or R<sup>9</sup> and R<sup>10</sup> together form a C<sub>3</sub>-C<sub>6</sub> cycloalkyl or C<sub>3</sub>-C<sub>6</sub> cycloalkenyl, and in either case wherein R<sup>9</sup> and R<sup>10</sup> are optionally substituted by C<sub>1</sub>-C<sub>4</sub> alkyl; and

R<sup>11</sup> is a C<sub>3</sub>-C<sub>10</sub> carbocyclic or C<sub>1</sub>-C<sub>10</sub> alkyl substituted by a C<sub>3</sub>-C<sub>10</sub> carbocyclic group.

23. (NEW) The compound according to claim 22, wherein R<sup>11</sup> is a C<sub>3</sub>-C<sub>6</sub> cycloalkyl.

24. (NEW) The compound according to claim 22, wherein R<sup>11</sup> is a C<sub>1</sub>-C<sub>10</sub> alkyl substituted by an unsaturated C<sub>5</sub>-C<sub>8</sub> carbocyclic group.

25. (NEW) The compound according to claim 21 that is:

5-[R-2-(1*S*,2*S*-2-Cyclohexylcyclopentylamino)-1-hydroxyethyl]-8-hydroxy-1*H*-quinolin-2-one;

5-[R-2-(1*R*,2*R*-2-cyclohexylcyclopentylamino)-1-hydroxyethyl]-8-hydroxy-1*H*-quinolin-2-one;

5-[R-2-(1*R*,2*R*-bicyclopentyl-2-ylamino)-1-hydroxyethyl]-8-hydroxy-1*H*-quinolin-2-one; or

5-[R-2-(1*R*,2*R*-2-Benzylcyclopentylamino)-1-hydroxyethyl]-8-hydroxy-1*H*-quinolin-2-one.

26. (NEW) A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 21.

27. (NEW) A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 21 and at least one pharmaceutically acceptable carrier.

Restriction Requirement Dated May 8, 2009

Reply to Restriction Requirement Dated June 8, 2009


28. (NEW) A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 21 and a therapeutically effective amount of another drug substance selected from the group consisting of an anti-inflammatory, a bronchodilator, an antihistamine, an immunosuppressive and an anti-tussive.

29. (NEW) A method of treating a patient with a condition which is prevented or alleviated by activation of the  $\beta_2$ -adrenoreceptor by administering a therapeutically effective amount of at least one compound according to claim 21.

30. (NEW) A method of treating a patient with obstructive or inflammatory airways disease by administering a therapeutically effective amount of at least one compound according to claim 21.

31. (NEW) A process for the preparation of a compound of claim 21 in free or salt or solvate form comprising:

(A) reacting a compound of formula II:




or a protected form thereof wherein R<sup>1</sup> and R<sup>2</sup> are as defined in claim 21, with a compound of formula III:



where G is a group of formula Ib:

Restriction Requirement Dated May 8, 2009

Reply to Restriction Requirement Dated June 8, 2009




or a protected form thereof wherein R<sup>7</sup>, R<sup>8</sup>, R<sup>9</sup>, R<sup>10</sup> and R<sup>11</sup> are as defined in claim 21;  
and

(B) recovering the resultant compound of formula I in free or salt or solvate form.

32. (NEW) A process for the preparation of a compound of claim 21 in free or salt or solvate form comprising:

(A) reducing a compound of formula IV:



or a protected form thereof wherein R<sup>1</sup>, R<sup>2</sup> and G are as defined in claim 21, to convert the indicated keto group into -CH(OH); and

(B) recovering the resultant compound of formula I in free or salt or solvate form.